| Estimated outcomes at week 48% and 95% CI | ||
| TC/T2T | Usual Care | |
| ASAS HI significant improvement | 47.3% (95% CI 36.2% to 59.0%) | 36.1% (95% CI 25.6% to 46.6%) |
| ASDAS LDA | 76.5% (95% CI 67.2% to 85.8%) | 59.5% (95% CI 48.7% to 70.3%) |
| ASDAS ID | 25.9% (95% CI 16.3% to 35.5%) | 18.7% (95% CI 10.2% to 27.2%) |
| ASDAS CII | 61.2% (95% CI 50.5% to 71.9%) | 46.0% (95% CI 35.1%; 56.9%) |
| ASDAS MI | 16.5% (95% CI 8.4% to 24.6%) | 14.9% (95% CI 7.1% to 22.7%) |
| ASAS40 | 52.3% (95% CI 41.4%; 63.2%) | 34.7% (95% CI 24.3% to 45.1%) |
| ASAS20 | 94.9% (95% CI 90.1% to 99.7%) | 85.9% (95% CI 78.0% to 93.0%) |
| BASDAI 50 | 79.0% (95% CI 70.1% to 87.9%) | 43.8% (95% CI 32.9% to 54.7%) |
| Physician global (0–10) | 2.0 (95% CI 1.9 to 2.1) | 1.8 (95% CI 1.78 to 1.8) |
| CRP (mg/L) | 3.9 (95% CI 3.6 to 4.2) | 3.5 (95% CI 3.2 to 3.8) |
| BASG (0–10) | 2.6 (95% CI 2.5 to 2.7) | 3.4 (95% CI 3.3 to 3.5) |
| BASFI (0–10) | 1.7 (95% CI 1.6 to 1.8) | 2.4 (95% CI 2.3 to 2.5) |
| EQ5D-5L | 0.7 (95% CI 0.7 to 0.7) | 0.8 (95% CI 0.8 to 0.8) |
| ASAS-NSAID score | 1.5 (95% CI 1.0 to 2.0) | −4.9 (95% CI −5.5 to −4.3) |
ASAS-HI, ASAS health index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CII, clinically important improvement; CRP, C reactive protein; EQ5D, EuroQol 5 domains and 5 levels; ID, inactive disease; LDA, low disease activity; MI, major improvement; TC/T2T, tight control/treat to target.